1887

Journal of Medical Microbiology logo

Volume 63, Issue 12

Whole glucan particles as a vaccine against murine aspergillosis Free

Abstract

Vaccination with heat-killed (HKY) protects against experimental infection by pathogenic fungi of five genera. Here we tested whether purified cell wall β-glucan could induce protection against systemic aspergillosis. CD-1 mice were given three weekly vaccine doses subcutaneously prior to intravenous infection with . Mice received PBS, 2.5 mg HKY, whole glucan particles (WGP), WGP conjugated to BSA (0.06 to 12 mg per dose), a soluble medium molecular mass (MMW) β-glucan alone or MMW–BSA (≤24 mg per dose). Survival and c.f.u. were determined, and cytokine induction and anti-β-glucan antibodies were assessed in vaccinated mice. Neither soluble MMW glucan, nor MMW–BSA was effective. HKY protected in two studies (survival and c.f.u. were reduced in brain and kidney organs, <0.004). Six or 12 mg WGP or WGP–BSA prolonged survival (≤0.004) and reduced c.f.u. in each organ (≤0.015) in both experiments; 0.6 mg WGP or WGP–BSA prolonged survival (≤0.015) and reduced c.f.u. (≤0.015) in one experiment. Cytokine profiles in serum and bronchoalveolar lavage from uninfected vaccinated mice showed an innate and adaptive immune profile (i.e. upregulation of colony stimulating factors, interferons, TNF-α, chemokines such as MCP-1, MIP-1α, RANTES and KC, and Th17-activating cytokines such as IL-6, IL-1β, IL-17). No anti-β-glucan antibodies were in the sera, suggesting an adaptive T cell-mediated, not a B cell-mediated, protective response. Vaccination with WGP or WGP–BSA proved protective against systemic aspergillosis, equivalent to that of HKY, supporting the potential of particulate β-glucans, alone or conjugated, as vaccines against aspergillosis.

  • Received:
  • Accepted:
  • Published Online:
© 2014 The Authors
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.079681-0
2014-12-01
2024-04-25
Loading full text...

Full text loading...

/deliver/fulltext/jmm/63/12/1750.html?itemId=/content/journal/jmm/10.1099/jmm.0.079681-0&mimeType=html&fmt=ahah

References

  1. Ahmad S., Tester R. F., Corbett A., Karkalas J. 2006; Dextran and 5-aminosalicylic acid (5-ASA) conjugates: synthesis, characterisation and enzymic hydrolysis. Carbohydr Res 341:2694–2701 [View Article][PubMed]
     [Google Scholar]
  2. Bailey R. W. 1958; The reaction of pentoses with anthrone. Biochem J 68:669–672[PubMed]
     [Google Scholar]
  3. Bozza S., Gaziano R., Lipford G. B., Montagnoli C., Bacci A., Di Francesco P., Kurup V. P., Wagner H., Romani L. 2002; Vaccination of mice against invasive aspergillosis with recombinant Aspergillus proteins and CpG oligodeoxynucleotides as adjuvants. Microbes Infect 4:1281–1290 [View Article][PubMed]
     [Google Scholar]
  4. Bystrický S., Machová E., Bartek P., Kolarova N., Kogan G. 2000; Conjugation of yeast mannans with protein employing cyanopyridinium agent (CDAP) – an effective route of antifungal vaccine preparation. Glycoconj J 17:677–680 [View Article][PubMed]
     [Google Scholar]
  5. Capilla J., Clemons K. V., Liu M., Levine H. B., Stevens D. A. 2009; Saccharomyces cerevisiae as a vaccine against coccidioidomycosis. Vaccine 27:3662–3668 [View Article][PubMed]
     [Google Scholar]
  6. Cassone A., Torosantucci A. 2006; Opportunistic fungi and fungal infections: the challenge of a single, general antifungal vaccine. Expert Rev Vaccines 5:859–867 [View Article][PubMed]
     [Google Scholar]
  7. Cenci E., Mencacci A., Bacci A., Bistoni F., Kurup V. P., Romani L. 2000; T cell vaccination in mice with invasive pulmonary aspergillosis. J Immunol 165:381–388 [View Article][PubMed]
     [Google Scholar]
  8. Clemons K. V., Antonysamy M. A., Danielson M. E., Michel K. S., Martinez M., Chen V., Stevens D. A. 2014; Whole glucan particles (WGP) as a vaccine against systemic coccidioidomycosis. In Interscience Conference on Antimicrobial Agents Chemotherapy abstract G-1894 Washington, DC: American Society for Microbiology;
     [Google Scholar]
  9. Committee for the update of the Guide for the Care and Use of Laboratory Animals 2011 Guide for the Care and Use of Laboratory Animals, 8th edn. Washington, DC: The National Academies Press;
     [Google Scholar]
  10. Danielson M. E., Dauth R., Elmasry N. A., Langeslay R. R., Magee A. S., Will P. M. 2010; Enzymatic method to measure β-1,3-β-1,6-glucan content in extracts and formulated products (GEM assay). J Agric Food Chem 58:10305–10308 [View Article][PubMed]
     [Google Scholar]
  11. Dasbach E. J., Davies G. M., Teutsch S. M. 2000; Burden of aspergillosis-related hospitalizations in the United States. Clin Infect Dis 31:1524–1528 [View Article][PubMed]
     [Google Scholar]
  12. Denning D. W., Stevens D. A. 1991; Efficacy of cilofungin alone and in combination with amphotericin B in a murine model of disseminated aspergillosis. Antimicrob Agents Chemother 35:1329–1333 [View Article][PubMed]
     [Google Scholar]
  13. Hanson L. H., Clemons K. V., Denning D. W., Stevens D. A. 1995; Efficacy of oral saperconazole in systemic murine aspergillosis. J Med Vet Mycol 33:311–317 [View Article][PubMed]
     [Google Scholar]
  14. Herbrecht R., Denning D. W., Patterson T. F., Bennett J. E., Greene R. E., Oestmann J. W., Kern W. V., Marr K. A., Ribaud P.& other authors ( 2002; Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347:408–415 [View Article][PubMed]
     [Google Scholar]
  15. Hong F., Yan J., Baran J. T., Allendorf D. J., Hansen R. D., Ostroff G. R., Xing P. X., Cheung N. K., Ross G. D. 2004; Mechanism by which orally administered β-1,3-glucans enhance the tumoricidal activity of antitumor monoclonal antibodies in murine tumor models. J Immunol 173:797–806 [View Article][PubMed]
     [Google Scholar]
  16. Huang H., Ostroff G. R., Lee C. K., Wang J. P., Specht C. A., Levitz S. M. 2009; Distinct patterns of dendritic cell cytokine release stimulated by fungal β-glucans and Toll-like receptor agonists. Infect Immun 77:1774–1781 [View Article][PubMed]
     [Google Scholar]
  17. Huang H., Ostroff G. R., Lee C. K., Agarwal S., Ram S., Rice P. A., Specht C. A., Levitz S. M. 2012; Relative contributions of dectin-1 and complement to immune responses to particulate β-glucans. J Immunol 189:312–317 [View Article][PubMed]
     [Google Scholar]
  18. Hurtgen B. J., Hung C. Y., Ostroff G. R., Levitz S. M., Cole G. T. 2012; Construction and evaluation of a novel recombinant T cell epitope-based vaccine against coccidioidomycosis. Infect Immun 80:3960–3974 [View Article][PubMed]
     [Google Scholar]
  19. Ito J. I., Lyons J. M. 2002; Vaccination of corticosteroid immunosuppressed mice against invasive pulmonary aspergillosis. J Infect Dis 186:869–871 [View Article][PubMed]
     [Google Scholar]
  20. Ito J. I., Lyons J. M., Hong T. B., Tamae D., Liu Y. K., Wilczynski S. P., Kalkum M. 2006; Vaccinations with recombinant variants of Aspergillus fumigatus allergen Asp f 3 protect mice against invasive aspergillosis. Infect Immun 74:5075–5084 [View Article][PubMed]
     [Google Scholar]
  21. Lachin J. M. 1999; Worst-rank score analysis with informatively missing observations in clinical trials. Control Clin Trials 20:408–422 [View Article][PubMed]
     [Google Scholar]
  22. Liu M., Clemons K., Bystricky S., Stevens D. 2010; Glycans and conjugates as vaccines against coccidioidomycosis. In 50th Interscience Conference on Antimicrobial Agents and Chemotherapy abstract G1-1657 Washington, DC: American Society for Microbiology;
     [Google Scholar]
  23. Liu M., Capilla J., Johansen M. E., Alvarado D., Martinez M., Chen V., Clemons K. V., Stevens D. A. 2011a; Saccharomyces as a vaccine against systemic aspergillosis: ‘the friend of man’ a friend again?. J Med Microbiol 60:1423–1432 [View Article][PubMed]
     [Google Scholar]
  24. Liu M., Clemons K. V., Bigos M., Medovarska I., Brummer E., Stevens D. A. 2011b; Immune responses induced by heat killed Saccharomyces cerevisiae: a vaccine against fungal infection. Vaccine 29:1745–1753 [View Article][PubMed]
     [Google Scholar]
  25. Liu M., Clemons K. V., Johansen M. E., Martinez M., Chen V., Stevens D. A. 2012a; Saccharomyces as a vaccine against systemic candidiasis. Immunol Invest 41:847–855 [View Article][PubMed]
     [Google Scholar]
  26. Liu M., Machová E., Neščáková Z., Medovarská I., Clemons K. V., Martinez M., Chen V., Bystrický S., Stevens D. A. 2012b; Vaccination with mannan protects mice against systemic aspergillosis. Med Mycol 50:818–828 [View Article][PubMed]
     [Google Scholar]
  27. Luo G., Gebremariam T., Clemons K. V., Stevens D. A., Ibrahim A. S. 2014; Heat-killed yeast protects diabetic ketoacidotic-steroid treated mice from pulmonary mucormycosis. Vaccine 32:3573–3576 [View Article][PubMed]
     [Google Scholar]
  28. Luque J. C., Clemons K. V., Stevens D. A. 2003; Efficacy of micafungin alone or in combination against systemic murine aspergillosis. Antimicrob Agents Chemother 47:1452–1455 [View Article][PubMed]
     [Google Scholar]
  29. Magee A., Rolke J., Yang R., Gerstner J. 2007; Glucan preparations. International Patent Application WO2007/146416 A2.
    [Google Scholar]
  30. Majumder T., Liu M., Chen V., Martinez M., Alvarado D., Clemons K. V., Stevens D. A. 2014; Killed Saccharomyces cerevisiae protects against lethal challenge of Cryptococcus grubii. Mycopathologia 178:189–195 [View Article][PubMed]
     [Google Scholar]
  31. Manners D. J., Masson A. J., Patterson J. C. 1973; The structure of a β-(1→3)-D-glucan from yeast cell walls. Biochem J 135:19–30[PubMed]
     [Google Scholar]
  32. Marr K. A., Patterson T., Denning D. 2002; Aspergillosis: pathogenesis, clinical manifestations, and therapy. Infect Dis Clin North Am 16:875–894 [View Article][PubMed]
     [Google Scholar]
  33. Nanjappa S. G., Heninger E., Wüthrich M., Gasper D. J., Klein B. S. 2012; Tc17 cells mediate vaccine immunity against lethal fungal pneumonia in immune deficient hosts lacking CD4+ T cells. PLoS Pathog 8:e1002771 [View Article][PubMed]
     [Google Scholar]
  34. Pelizon A. C., Kaneno R., Soares A. M., Meira D. A., Sartori A. 2005; Immunomodulatory activities associated with β-glucan derived from Saccharomyces cerevisiae. Physiol Res 54:557–564[PubMed]
     [Google Scholar]
  35. Shih W. 2002; Problems in dealing with missing data and informative censoring in clinical trials. Curr Control Trials Cardiovasc Med 3:4 [View Article][PubMed]
     [Google Scholar]
  36. Soltanian S., Stuyven E., Cox E., Sorgeloos P., Bossier P. 2009; β-glucans as immunostimulant in vertebrates and invertebrates. Crit Rev Microbiol 35:109–138 [View Article][PubMed]
     [Google Scholar]
  37. Steinbach W. J., Stevens D. A. 2003; Review of newer antifungal and immunomodulatory strategies for invasive aspergillosis. Clin Infect Dis 37:Suppl. 3S157–S187 [View Article][PubMed]
     [Google Scholar]
  38. Stevens D. A. 2000; Aspergillosis. In Cecil Textbook of Medicine pp. 1875–1877 Edited by Goldman L., Bennett J. C. Philadelphia: W.B. Saunders;
     [Google Scholar]
  39. Stevens D. A. 2004; Vaccinate against aspergillosis! A call to arms of the immune system. Clin Infect Dis 38:1131–1136 [View Article][PubMed]
     [Google Scholar]
  40. Stevens D. A., Clemons K. V., Liu M. 2011; Developing a vaccine against aspergillosis. Med Mycol 49:Suppl. 1S170–S176 [View Article][PubMed]
     [Google Scholar]
  41. Sugar A. M., Brummer E., Stevens D. A. 1983; Murine pulmonary macrophages: evaluation of lung lavage fluids, miniaturized monolayers, and candidacidal activity. Am Rev Respir Dis 127:110–112[PubMed]
     [Google Scholar]
  42. Tian J., Ma J., Ma K., Ma B., Tang X., Baidoo S. E., Tong J., Yan J., Lu L.& other authors ( 2012; Up-regulation of GITRL on dendritic cells by WGP improves anti-tumor immunity in murine Lewis lung carcinoma. PLoS ONE 7:e46936 [View Article][PubMed]
     [Google Scholar]
  43. Torosantucci A., Bromuro C., Chiani P., De Bernardis F., Berti F., Galli C., Norelli F., Bellucci C., Polonelli L.& other authors ( 2005; A novel glyco-conjugate vaccine against fungal pathogens. J Exp Med 202:597–606 [View Article][PubMed]
     [Google Scholar]
  44. Torosantucci A., Chiani P., Bromuro C., De Bernardis F., Palma A. S., Liu Y., Mignogna G., Maras B., Colone M.& other authors ( 2009; Protection by anti-β-glucan antibodies is associated with restricted β-1,3 glucan binding specificity and inhibition of fungal growth and adherence. PLoS ONE 4:e5392 [View Article][PubMed]
     [Google Scholar]
  45. Warnock D. W. 2006; Fungal diseases: an evolving public health challenge. Med Mycol 44:697–705 [View Article][PubMed]
     [Google Scholar]
  46. Wuthrich M., Filutowicz H. I., Warner T., Deepe G. S. Jr, Klein B. S. 2003; Vaccine immunity to pathogenic fungi overcomes the requirement for CD4 help in exogenous antigen presentation to CD8+ T cells: implications for vaccine development in immune-deficient hosts. J Exp Med 197:1405–1416 [View Article][PubMed]
     [Google Scholar]
  47. Yan J., Allendorf D. J., Brandley B. 2005; Yeast whole glucan particle (WGP) β-glucan in conjunction with antitumour monoclonal antibodies to treat cancer. Expert Opin Biol Ther 5:691–702 [View Article][PubMed]
     [Google Scholar]
  48. York W. S., Darvill A. G., McNeil M., Stevenson T. T., Albersheim P. 1986; Isolation and characterization of plant cell walls and cell wall components. Methods Enzymol 118:3–40 [View Article]
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.079681-0
Loading
Whole glucan particles as a vaccine against murine aspergillosis
J. Med. Microbiol. 63, 1750 (2014); https://doi.org/10.1099/jmm.0.079681-0
/content/journal/jmm/10.1099/jmm.0.079681-0
/content/journal/jmm/10.1099/jmm.0.079681-0
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error